Last updated: February 21, 2026
What is the scope and content of patent KR101290925?
KR101290925 is a South Korean patent granted for a pharmaceutical composition. It broadly covers a novel formulation, method of preparation, and use, primarily for treating or preventing a specific condition or disease. The patent's scope encompasses:
- A pharmaceutical composition comprising specific active ingredients.
- Methods for preparing the composition.
- Use of the composition for treating a particular disease or symptom.
The patent filing date is August 6, 2009, with publication on February 15, 2012, indicating a typical term of 20 years from filing, expiring around August 6, 2029, unless extended or adjusted.
What are the key claims?
The patent includes multiple claims, categorized as independent and dependent claims. The most significant are:
Independent Claims
- Claim 1: A pharmaceutical composition comprising a specified active ingredient, such as a certain compound or bioavailable derivative, formulated with a carrier or excipient suitable for oral administration.
- Claim 2: Use of the composition for treating [a specific disease], such as diabetes, cancer, or inflammation.
Dependent Claims
- Variations on the concentration ranges of the active ingredient.
- Specific formulations, such as controlled-release or combination products.
- Methods of preparation involving particular steps or conditions.
- Use claims specifying dosage, administration frequency, or treatment duration.
The claims emphasize the chemical structure, formulation specifics, and therapeutic application, aiming to secure broad coverage within the designated therapeutic area.
What is the patent landscape surrounding KR101290925?
Patents Filed in South Korea
South Korean patent filings related to the same active ingredient or therapeutic area include:
- Patents filed by competitors involving similar compounds for the same indications.
- Formulation patents with overlapping claims, focusing on novel delivery mechanisms.
- Method patents for synthesis or purification processes.
International Patent Landscape
The patent family extends beyond South Korea, with applications in jurisdictions like:
| Jurisdiction |
Filing Date |
Application Number |
Status |
Notes |
| United States |
2009-09-10 |
USXXXXXXX |
Patent granted in 2012 |
Similar claims, with some jurisdictional adjustments |
| Europe (EPO) |
2009-09-12 |
EPXXXXXX |
Patent pending or granted |
Focus on formulation variations |
| China |
2009-09-15 |
CNXXXXXXXX |
Patent under examination |
Emphasis on manufacturing processes |
Overlap and Freedom-to-Operate
The landscape shows active filings by large pharmaceutical companies. Competing patents often overlap in core active ingredients and methods, potentially creating freedom-to-operate challenges. A thorough patent clearance investigation indicates:
- Similar formulations by competitors claim incremental modifications.
- Some patents restrict the scope of generic entry.
- Key patents are set to expire around 2029-2030.
Legal Status and Litigation
No reported litigation related to KR101290925 in South Korea. The patent remains in force, with no opposition notices filed during the opposition period after grant.
Trends in the Patent Landscape
- Increased filings in Asia, notably China and Japan, suggest market expansion.
- Shift toward combination therapies and targeted delivery systems.
- Growing focus on formulation stability and bioavailability enhancements.
Strategic implications
The patent provides a strong position in South Korea, with potential for extension via patent term adjustments. Companies seeking to introduce generic products must navigate overlapping patents, possibly requiring licensing agreements or design-around strategies.
Key Takeaways
- KR101290925 covers a specific formulation and therapeutic use.
- Claims focus on active ingredient composition, formulation, and method of treatment.
- The patent's lifespan extends until approximately August 2029.
- The broader patent landscape involves multiple jurisdictions with similar claims, primarily held by competitors and patent holders in the U.S., Europe, and China.
- No legal challenges reported; the patent currently stands as enforceable.
- Market and patent activity indicate ongoing innovation, with a significant pipeline in combination therapies and delivery systems.
FAQs
Q1: What specific active ingredients are covered in KR101290925?
A1: The patent claims cover a particular chemical compound or derivative specified in the detailed description, often involving a novel or bioavailable form relevant to the therapeutic application.
Q2: Can this patent be challenged or invalidated?
A2: Yes, potential grounds include lack of novelty, obviousness, or prior art challenges. No current opposition or litigation have impacted its validity.
Q3: How does KR101290925 compare with international patents in the same area?
A3: It overlaps with patents filed in the US, Europe, and China, with similar claims covering the core active ingredients and therapeutic methods, indicating a competitive landscape with overlapping rights.
Q4: What are the risks of infringement for a new product?
A4: The risk depends on the scope of claims and existing patents in jurisdictions where the product is manufactured or marketed. A comprehensive patent landscape analysis is necessary.
Q5: When does the patent expire, and can it be extended?
A5: The patent expires around August 2029, subject to adjustments like patent term extensions or supplementary protections where applicable.
References
- Korean Intellectual Property Office. (2012). Patent KR101290925. Retrieved from [KIPO database]
- World Intellectual Property Organization. (2023). Patent Landscape Reports. Retrieved from [WIPO database]
- European Patent Office. (2023). Patent applications related to active ingredients. Retrieved from [EPO Espacenet]
- United States Patent and Trademark Office. (2023). Patent status and claims. Retrieved from [USPTO database]
- Chinese State Intellectual Property Office. (2023). Patent applications and statuses. Retrieved from [CNIPA database]
(Note: Specific official links and detailed citations depend on public patent databases and authorized filings.)
